68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

计划入组 10 人 · 首次发布于 2025 年 2 月 28 日

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

计划入组 45 人 · 首次发布于 2024 年 8 月 28 日

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

计划入组 44 人 · 首次发布于 2024 年 12 月 17 日

Lutetium Lu-177 vipivotide tetraxetan(Pluvicto)

C₄₉H₆₈LuN₉O₁₆

177Lu-EB-PSMA-617

Gallium-68 PSMA-617

ImmusanT, Inc.

United States

LTB4 Sweden AB

Sweden

Hexal AG

Germany

Radionuclide Therapy Shows Promise in Advanced Prostate Cancer Treatment

Lutetium-177-PSMA-617 Shows Promise in Advanced Prostate Cancer Treatment

Archeus Technologies Initiates First-in-Human Trial of ART-101 PSMA-Targeting Radioligand Therapy for Metastatic Prostate Cancer